Comparison of breast cancer HER-2 receptor testing with immunohistochemistry and in situ hybridization.

Autor: Shanmugalingam A; Western Sydney Local Health District, Westmead Hospital, Cnr Hawkesbury Road and Darcy Rd, Westmead NSW 2145, Sydney, Australia. aswin.shanmugalingam@health.nsw.gov.au., Hitos K; Western Sydney Local Health District, Westmead Hospital, Cnr Hawkesbury Road and Darcy Rd, Westmead NSW 2145, Sydney, Australia.; Sydney Medical School, University of Sydney, Sydney, Australia., Pathmanathan N; Western Sydney Local Health District, Westmead Hospital, Cnr Hawkesbury Road and Darcy Rd, Westmead NSW 2145, Sydney, Australia.; Westmead Breast Cancer Institute, Westmead Hospital, Sydney, Australia., Edirimmane S; Sydney Medical School, University of Sydney, Sydney, Australia.; Nepean Blue Mountains Local Health District, Sydney, Australia.; Northern Surgical Oncology, Sydney, Australia.; Sydney Adventist Hospital, Sydney, Australia., Hughes TM; Northern Surgical Oncology, Sydney, Australia.; Sydney Adventist Hospital, Sydney, Australia.; Australian National University, Canberra, Australia., Ngui NK; Western Sydney Local Health District, Westmead Hospital, Cnr Hawkesbury Road and Darcy Rd, Westmead NSW 2145, Sydney, Australia.; Northern Surgical Oncology, Sydney, Australia.; Sydney Adventist Hospital, Sydney, Australia.; Australian National University, Canberra, Australia.; Western Sydney University, Sydney, Australia.
Jazyk: angličtina
Zdroj: Breast cancer research and treatment [Breast Cancer Res Treat] 2023 Feb; Vol. 198 (1), pp. 143-148. Date of Electronic Publication: 2023 Jan 05.
DOI: 10.1007/s10549-023-06860-z
Abstrakt: Purpose: Human epidermal growth factor receptor-2 (HER2) status can be tested with immunohistochemistry (IHC) and in situ hybridization (ISH). The 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) HER2 testing guidelines suggest initial HER2 testing using IHC and further testing IHC equivocal cases with ISH. However, many institutions perform both IHC and ISH on the same specimen. This study aims to analyze the concordance between HER2 IHC and ISH in order to evaluate the benefit of repeating HER2 testing on the same breast cancer specimens.
Method: Patients diagnosed with invasive breast cancer through BreastScreen NSW Sydney West program between January 2018 and December 2020 were identified and their HER2 IHC and HER2 ISH results on core needle biopsy (CNB) and surgical excisions (SE) were retrospectively collected. Specimens with both IHC and ISH results were then analyzed for agreement and concordance using unweighted kappa values. Equivocal IHC (2+) cases were excluded from concordance analysis.
Results: Overall, there were 240 invasive breast cancer specimens (CNB and SE) with both IHC and ISH recorded. Concordance between HER2 IHC and ISH was 100% (95% CI: 96.2-100%; κ = 1.00 (P < 0.001)). Of the IHC equivocal cases (n = 146), 94.5% were ISH negative.
Conclusion: There was perfect positive concordance and agreement between non-equivocal IHC and ISH results. This reinforces that IHC alone can be utilized reliably for testing HER2 status of non-equivocal cases consistent with the 2018 ASCO/CAP guidelines.
(© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: